Recently, our portfolio company Accure Therapeutics announced the successful results of the ACUITY phase 2 trial in collaboration with Oculis.
Accure Therapeutics, a pioneering translational neuroscience R&D company, has made significant strides in the field of eye care through its innovative drug development efforts.
Key achievements include:
- Phase 2 trial with lead neuroprotective molecule OCS-05 (formerly ACT-01) completed by licensing partner Oculis met primary safety endpoint and key secondary efficacy endpoints with no serious adverse events
- Trial success clearly supports Accure’s translational approach to drug development and partnership business model
- Accure has two other assets in the pipeline to treat range of central nervous system (CNS) disorders
Read the full announcement here.
